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1. Introduction 
In 1897 Felix Hoffman, a 29-year-old scientist working for the Bayer Company patented a 
chemical procedure that enabled the acetylation of salicylic acid with the enough purity to 
be used commercially (Wallace, 1997). The new product was evaluated by Dreser Heinrich, 
head of marketing at Bayer, who - despite some initial misgivings - gave his approval for 
marketing acetylsalicylic acid under the name "Aspirin" in 1899. The new compound was 
commercialized by Bayer as an effective therapy for fever and aches, one that, unlike its 
source molecule (salicylic acid), had no gastric side effects. For over six decades aspirin 
remained the mainstay of non-narcotic analgesic treatment and nonsteroidal anti-
inflammatory drug (NSAIDs) therapy. Beginning with the sale of indomethacin in 1963, 
used for the treatment of rheumatoid arthritis, at least twenty other NSAIDs with aspirin-
like actions have been developed over the past half-century. Although aspirin's preeminence 
as an over-the-counter analgesic has been progressively displaced by new NSAIDs, new 
studies exploring its antiplatelet effect led to aspirin's development as a major 
antithrombotic agent (Patrono et al., 2005). Today, NSAIDs are popular because of their 
versatile effectiveness as analgesics, antipyretics, and as anti-inflammatory agents, and they 
remain among the most frequently prescribed medications worldwide.  
The long-standing confidence in the gastric safety of aspirin went unchallenged for 40 years 
until 1938 when two researchers at Guy's Hospital in London, Douthwaite and Lintott, 
showed unquestionably that it had a major gastro-erosive activity (Douthwaite  & Lintott 
1938). Unfortunately, most of the NSAIDs currently available on the market can injure the 
gastric and duodenal mucosa (Cryer  & Feldman, 1992; Soll et al., 1991), much like aspirin, 
with considerable rates of morbidity and mortality. The standard evolution of peptic ulcers 
resulting from NSAIDs ranges from resolution without intervention to the development of 
complications, such as bleeding and perforation. To variable degrees aspirin and NSAIDs 
inhibit the cyclooxygenase (COX) enzymes COX-1 and COX-2, which synthesize the 
inflammatory mediators known as prostaglandins and thromboxane. Prostaglandin 
inhibition plays a critical role in the pathogenesis of NSAIDs-induced gastric injury. 
Beginning ten years ago new specific inhibitors of COX-2 became available, compounds that 
have significantly reduced gastrointestinal (GI) side effects compared with COX-1 inhibitors 
(Bombardier et al., 2000; Laine et al., 2007; Silverstein et al., 2000).  
Peptic ulcers are defects in the GI mucosa that extend throughout the muscularis mucosae, 
and which are often associated with Helicobacter pylori (H. pylori) infection or with 
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consumption of NSAIDs. As the prevalence of H. pylori infection has declined in Western 
countries, gastric ulcers have increasingly been linked to NSAID use, with acetylsalicylic 
acid (Yuan et al., 2006) being an important cause of morbidity and rising health care costs 
related to work loss, hospitalization, and outpatient care (Ramakrishnan  & Salinas, 2007). 
Management of peptic ulcer disease has improved radically during the past few decades, 
culminating in the widespread use of proton pump inhibitor (PPI)-based triple therapy for 
H. pylori eradication. However, prescriptions for drugs such as aspirin and NSAIDs have 
also increased over this same time period and adherence to gastroprotection protocols to 
prevent NSAID-induced peptic ulcer disease still seem to be far from optimal (Jones, 2001). 
2. Epidemiology 
2.1 Ulcers and NSAIDs. Incidence and prevalence 
In the United States alone sales of over-the-counter analgesics approach 3 billion dollars 
annually, with NSAIDs accounting for about 60% of sales (the other 40% is attributed to 
acetaminophen) (Laine, 2001). An estimated 14 million patients use NSAIDs for the relief of 
symptoms associated with arthritis alone (Wolfe, 1996), and among patients older that 65, as 
many as 70% take NSAIDs at least once a week, with at least 34% of this population taking a 
NSAID tablet daily (Talley et al., 1995).  
A systematic review of the worldwide literature estimated that the annual incidence of 
peptic ulcer disease ranged from 0.1 to 0.19 percent for physician-diagnosed and 0.01 to 0.17 
percent when based upon hospitalized patients (Sung et al., 2009). Upper GI symptoms, 
such as dyspepsia, occur in 15% to 60% of NSAID users, twice as often as in individuals not 
taking NSAIDs. The prevalence of gastric or duodenal ulcers in patients taking NSAIDs 
regularly is approximately 15% to 30%. The annual incidence of NSAID-related clinical 
upper GI events (complicated and symptomatic ulcers) is approximately 2.5% to 4.5%, with 
the annual incidence of serious complications (severe bleeding, perforation, and obstruction) 
running about 1% to 1.5% (Laine, 2002).  
2.2 Trends  
The epidemiology of peptic ulcer disease largely reflects environmental factors, primarily H. 
pylori infection, but also NSAID use and smoking. The incidence of H. pylori below age 50 is 
falling dramatically in developed countries due, in part, to improved hygiene and 
socioeconomic conditions; however, the prevalence of H. pylori infection remains high for 
older individuals and in certain predisposed subpopulations.  The epidemiology of peptic 
ulcer disease has changed in the past decade due to the enormous efforts made to eradicate 
H. pylori infection, which is the single largest cause of peptic ulcers. As the prevalence of H. 
pylori infection has declined, the proportion (and actual numbers) of patients with H. pylori-
negative idiopathic ulcers, and with ulcers attributed to the use of NSAIDs, has risen (Chow  
& Sung, 2007). A prospective cohort study in Hong Kong (Chan et al., 2001; Hung et al., 
2005) demonstrated that the number and proportion of H. pylori-associated ulcers decreased 
from 50.3% in 1997–1998 and to 33.4% in 2000–2001. This study also showed that there was a 
4.5-fold increase in the absolute number of idiopathic ulcers, from 4.1% to 18.8% during that 
same time period. By contrast, the relative proportion of NSAID-associated ulcers remained 
constant (45.5% in 1997–1998 versus 47.8% in 2000–2001). On the basis of these data, the 
incidence of non-H. pylori, non-NSAID peptic ulcer bleeding is thought to be on the rise in 
Asia. Similar prospective studies are awaited in the West; however, it is clear that the global 
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prevalence of idiopathic ulcers is on increasing. Although H. pylori is the predominant cause 
of peptic ulcer disease worldwide, it appears that there are regional differences in 
prevalence that cannot be explained by this infection per se. Patterns of NSAID use and 
smoking are likely to be important, too.  
At a minimum, smoking clearly exacerbates H. pylori-associated ulcer disease. The decline in 
smoking in younger individuals, particularly in males, and the concomitant increase in 
women, may be a factor in the declining male/female ratio of ulcer disease. Smoking does 
not appear to be a factor in the ulcerative complications found in older women or in NSAID-
related ulcers. It should also be borne in mind that NSAID use increases as a function of age 
and is an independent risk factor for ulcers. In addition, older subjects are more likely not 
only to develop complications from NSAID-related ulcers, but also to suffer increased 
morbidity and mortality from these complications because of co-morbidities. 
3. Mechanisms of therapeutic action of NSAIDs 
Based on their chemical structure, there are now at least 20 different NSAIDs from six major 
groups available for use in humans (Table 1). All of them are absorbed completely, have 
negligible first-pass hepatic metabolism, are tightly bound to albumin, and have small 
volumes of distribution. The half-lives of NSAIDs vary, though in general can be divided 
into "short" (less than six hours) and "long" (more than six hours) lasting drugs. These 
compounds differ in their doses, interaction with other drugs, and some specific side effects. 
The inhibition of prostaglandin synthesis via the blockade of cyclooxygenase (COX) has 
been widely accepted as the main mechanism of action and toxicity utilized by these 
compounds (Moncada et al., 1973). However, during the last decade, many groups have 
described a number of non-prostaglandin-mediated anti-inflammatory effects from NSAIDs, 
suggesting that COX inhibition is not the only explanation for either the anti-inflammatory 
action or the gastric toxicity observed with this group of therapeutic agents (Abramson  & 
Weissmann, 1989; Amin et al., 1995; Kopp  & Ghosh, 1994; Mahmud et al., 1996). 
 
 
Non-selective nonsteroidal anti-inflammatory (NSAID) agents 
 Salicylate (acetylated): Aspirin 
 Salicylates (non-acetylated): Diflunisal, Choline magnesium trisalicylate, Salsalate 
 Propionic acids: Ibuprofen, Naproxen, Ketoprofen, Flurbiprofen, Oxaprozin 
 Acetic acids: Diclofenac, Etodolac, Tolmetin, Sulindac, Ketorolac, Indomethacin  
 Oxicams (enolic acids): Meloxicam, Piroxicam 
 Fenamates (anthranilic acids): Meclofenamic acid, Mefenamic acid 
 Non-acidic (naphthylalkanone): Nabumetone 
 
Selective COX-2 inhibitors:  
 Celecoxib, Eterocoxib, Parecoxib 
Table 1. NSAID families 
3.1 COX inhibition 
As stated above, NSAIDs target COX, and hence the synthesis of prostaglandins, 
particularly prostaglandin E2 (PGE2). This inflammatory molecule lowers pain thresholds, 
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and the primary goal of NSAIDs is to reduce pain. Tissue prostaglandins are produced from 
membrane arachidonic acid via two pathways: cyclooxygenase-1 (COX-1) and COX-2. The 
COX-1 pathway is the predominant constitutive pathway; prostaglandins derived from this 
enzyme mediate many effects, most notably they facilitate gastroduodenal cytoprotection, 
renal perfusion, and platelet activity. In contrast, the COX-2 pathway is inducible by 
inflammatory stimuli and mediates effects through prostaglandins, which results in 
inflammation, pain, and fever. COX-2 induces at least two orders of magnitude more PGE2 
than COX-1. Specific inhibitors of COX-2 represent a major advance in the treatment of pain, 
particularly in patients with osteoarthritis or rheumatoid arthritis. For the most part, COX-2 
inhibitors have significantly reduced gastrointestinal side effects compared with COX-1 
inhibitors (Rostom et al., 2007).  
All of the non-salicylate, non-COX-2 selective NSAIDs including aspirin can interfere with 
platelet aggregation and secretion (McQueen et al., 1986; O'Brien, 1968) through the 
inactivation of platelet COX-1. In platelets, this enzyme is a rate-limiting step in the 
transformation of arachidonic acid into thromboxane A2, a potent platelet-aggregating 
agent. However, aspirin inhibits platelet COX-1 in an irreversible manner and thus has 
proven beneficial in reducing the risk of secondary thrombotic cardiovascular events 
(Berger et al., 2008). These properties may be important enough to warrant its continued use 
in those patients also needing common NSAIDs. Thus, if needed, such patients can be 
continued on low dose aspirin. Administration of some NSAIDs may interfere with the 
desirable antiplatelet effects of aspirin (Catella-Lawson et al., 2001). 
3.2 Nonprostaglandin-mediated effects 
Although NSAIDs' degree of potency as inhibitors of prostaglandin synthesis in vitro tends 
to reflect their anti-inflammatory potency in vivo, several experimental and clinical studies 
suggest that prostaglandin inhibition is only part of the story. The necessary dose of any 
given NSAID, notably aspirin, which is essential for suppressing inflammation, may well 
exceed that required to substantially inhibit prostaglandin synthesis, at least in plasma. In 
this regard, salicylate, which is a weak inhibitor of COX activity, appears to be as effective as 
aspirin, a potent inhibitor of COX activity, in controlling inflammation in patients with 
rheumatoid arthritis (Brooks  & Day, 1991). These and other data have led to the suggestion 
that these drugs are driven by prostaglandin-independent mechanistic actions, particularly 
in terms of their anti-inflammatory properties. 
Therefore, several non-prostaglandin-mediated NSAID-induced mechanisms of action may 
also be important. These mechanisms are generally related to the ability of NSAIDs to insert 
themselves into biological membranes and disrupt a wide range of cell functions and cell-
cell interactions. For example, NSAIDs might interfere with neutrophil-endothelial cell 
adherence by decreasing the availability of L-selectins in the membranes of neutrophils, 
thereby removing a critical step in the migration of granulocytes to sites of inflammation 
(Diaz-Gonzalez et al., 1995). NSAIDs also inhibit nuclear factor kappa B (NF-kB)-dependent 
transcription in vitro, resulting in a decrease in available nitric oxide synthetase (Amin et al., 
1995). This enzyme produces nitric oxide in large amounts, thereby causing vasodilation, 
cytotoxicity, and increased vascular permeability (Hawkey, 1995). The anti-nociceptive 
actions of some NSAIDs, though not all, appear to involve L-arginine-NO-cyclic GMP-
potassium channel pathways (Ortiz et al., 2003). 
The role and importance of these non-prostaglandin-mediated processes in clinical 
inflammation remains unclear. Also unknown is whether any of these potential 
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mechanisms of action might explain the great variability in individual patient response to 
NSAIDs. 
4. Mechanisms underlying NSAID-induced gastrointestinal toxicity  
NSAIDs damage gastrointestinal mucosa by causing both local injuries and by systemically 
inhibiting prostaglandin production. However, current consensus on the pathogenesis of 
symptomatic peptic ulcer disease resulting from exposure to NSAIDs holds that it is mainly 
a consequence of systemic (post-absorptive) inhibition of GI mucosal COX activity rather 
than a local effect (van Oijen et al., 2008).   
4.1 COX inhibition 
NSAIDs induce gastrointestinal cytotoxicity through the inhibition of COX enzyme activity, 
a correlation which has been well established (Warner et al., 1999). In addition, while it is 
now known that certain prostaglandins such as PGE2 reduce gastric acid secretion, the onset 
of hypochlorhydria does not entirely explain the mucosal protection observed with PGE2. 
This has led to the notion that prostaglandins have antisecretory-independent effects that 
have been collectively referred to as "cytoprotection". Some of the cytoprotective 
mechanisms employed by prostaglandins include stimulation of glycoprotein (mucin), 
bicarbonate and phospholipid production by epithelial cells, enhancement of mucosal blood 
flow and oxygen delivery to epithelial cells via local vasodilation, increased epithelial cell 
migration towards the luminal surface (restitution), and enhanced epithelial cell 
proliferation (Robert et al., 1979). Inhibition of the COX-1 pathway blocks production of 
prostaglandins in epithelial cells and, consequently, these compounds impair any protective 
capabilities, resulting in a gastric environment that is more susceptible to topical attack by 
endogenous factors, such as acid, pepsin, and bile salts. Many NSAIDs block COX-1 and 
COX-2 more or less equally (i.e., are non-selective) and thus they may impair gastric 
prostaglandin production even at low concentrations. Since prostaglandins are essential to 
both the maintenance of intact GI defenses and normal platelet function, NSAIDs promote 
ulcer formation as well as bleeding. Drugs that more selectively inhibit COX-2 than COX-1 
have less suppressive effects on gastric prostaglandin synthesis. As a result, selective 
inhibitors of COX-2 preserve prostaglandin-mediated GI mucosal protection. However, 
COX-2 selective inhibitors may still block COX-1 at clinically recommended doses, and thus 
have the potential to also block COX-1 in the stomach and duodenum and thereby cause 
damage.  
4.2 Nonprostaglandin-mediated effects 
Most NSAIDs are carboxylic acid derivatives. As a result, they are not ionized at the acidic 
pH levels found in the gastric lumen and can thus be absorbed across the gastric mucosa. 
Once the drug moves from the acidic environment of the gastric lumen into the pH–neutral 
mucosa, the drug ionizes and is trapped temporarily in epithelial cells where it may inflict 
damage.  
The ability to uncouple mitochondrial oxidative phosphorylation is a common characteristic 
of NSAIDs containing an ionizable group. NSAIDs are able to interfere with mitochondrial 
oxidative phosphorylation (Krause et al., 2003), reducing intracellular ATP synthesis in vivo 
(Mingatto et al., 1996), an effect that has been postulated as representing an early pathogenic 
event in NSAID-mediated enteropathy (Mahmud et al., 1996; Rainsford, 1980). Recently, 
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novel pathways, independent of COX inhibition, have been identified for some NSAIDs, as 
has their ability to bind and disrupt cell membranes. In vitro exposure of gastric epithelial 
cells to different concentrations of NSAIDs can result in altered cell-membrane permeability. 
This can lead to profound and rapid changes in cell morphology, suggesting that the 
cytotoxicity and biological actions of NSAIDs are mediated by the cell membrane and are 
not dependent upon COX (Zhou et al.).  
4.3 Role of Helicobacter pylori infection 
Until recently, data analysis on the role of H. pylori infection as a risk factor for GI bleeding 
in NSAID users was complicated by a failure, in many studies, to account for the variable 
influence of multiple, co-existing risk factors. Not surprisingly, therefore, these studies have 
yielded conflicting results (Graham et al., 1992).  
A comprehensive meta-analysis of 16 case–controlled studies demonstrated that the risk of 
peptic ulcer bleeding was increased by a factor of 1.79 with H. pylori infection, by 4.85 with 
NSAID usage, and by 6.13 in the presence of both NSAID use and H. pylori infection, 
strongly suggesting the possibility of an additive effect (Huang et al., 2002). Further 
evidence of H. pylori infection's additive role in the context of NSAID use comes from trials 
measuring the impact of H. pylori eradication. Indeed, the eradication of H. pylori in high-
risk patients prior to the initiation of NSAID therapy has been shown to significantly reduce 
the risk of subsequent ulceration (Bazzoli et al., 2001; Malfertheiner et al., 2002). Two 
systematic reviews have clearly shown that eradication of H. pylori is superior to placebo 
therapy in the primary prevention of peptic ulcers among NSAID users (risk ratio (95 % CI) 
0.35 (0.20 – 0.61)) (Leontiadis et al., 2007). Using a Markov model, Leontiadis et al. 
(Leontiadis et al., 2007) showed that the most cost-effective strategy for primary prevention 
of NSAID-associated ulcers was H. pylori eradication in patients over age 50. Interestingly, 
sensitivity analysis showed that eradication therapy remained cost-effective even when the 
H. pylori prevalence was as low as 5%. However, eradication seems less effective than 
treatment with a maintenance PPI for preventing non-steroidal anti-inflammatory drug-
associated ulcers (Vergara et al., 2005). 
It must be added that many patients take NSAIDs intermittently and often for only short 
periods at a time.  Whether a “test-and-treat” strategy would be cost effective for such a 
large population group is unknown. Furthermore, it has also been noted that eradication of 
H. pylori infection alone is not sufficient for the secondary prevention of peptic ulcer 
bleeding in chronic NSAID users (Vergara et al., 2005). 
5. Risk of GI complications in patients taking different NSAIDs 
Recent studies suggest that the risk of GI complications may be lower with the use of some 
NSAIDs, including ibuprofen, nabumetone, meloxicam, and etodolac, but higher with others 
such as sulindac, piroxicam, and ketorolac (de Abajo  & Garcia Rodriguez, 2001; Garcia 
Rodriguez  & Hernandez-Diaz, 2001; Hernandez-Diaz  & Rodriguez, 2000). In the case of 
ibuprofen, this may be due to the use, in general, of lower analgesic doses, especially in 
relation to ibuprofen preparations that are available over-the-counter. Nabumetone, 
meloxicam, and etodolac may possess some degree of COX-2 selectivity, whereas sulindac, 
piroxicam, and ketorolac may owe their increased toxicity to the presence of relatively long 
plasma half-lives, which would thereby result in more prolonged mucosal exposure (Simon  
& Mills, 1980). With respect to aspirin, its use at low doses alone, in the absence of other risk 
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factors, is also associated with an increased risk for both GI bleeding and death from GI 
complications. Numerous studies in patients taking low-dose aspirin alone have shown a 
relative risk of 2–4 for GI bleeding (Lanas et al., 2005). Furthermore, a large percentage of 
patients on low-dose aspirin are elderly, have multiple co-morbidities, and cardiovascular 
disease, in particular, and are likely to be concurrently taking anticoagulants, NSAIDs and 
corticosteroids, any one of which will elevate their relative risk for GI events to several times 
that of low-dose aspirin alone. It is important to emphasize that physicians are often 
unaware that patients are self-medicating with low-dose aspirin when they prescribe 
NSAIDs for pain relief or anti-inflammatory effects. 
In regards to COX-2 inhibitors, there have been several large randomized, controlled, outcome 
trials comparing COX-2 inhibitors to traditional NSAIDs. The CLASS study (Silverstein et al., 
2000) compared celecoxib 400 mg b.i.d. with ibuprofen 800 mg t.i.d., or diclofenac 75 mg b.i.d., 
in osteoarthritis or rheumatoid arthritis patients. A non-significant 50% reduction in ulcer 
complications was observed in the celecoxib group compared with those who received the 
conventional NSAID after 6 months of therapy. After 1 year, however, there was little or no 
difference between the three groups. Another large trial, the VIGOR study (Bombardier et al., 
2000), compared outcomes in rheumatoid arthritis patients taking either 500 mg of naproxen 
b.i.d. or 50 mg of rofecoxib daily. At 6 months, rofecoxib was associated with a significantly 
lower incidence of GI events (2.1 vs. 4.5%, P < 0.001), and GI complications (0.6 vs. 1.42 %, P = 
0.005). The TARGET study (Schnitzer et al., 2004) compared lumiracoxib with traditional 
NSAIDs in patients with osteoarthritis. After 1 year, a significant reduction in ulcer 
complication rates was noted for lumiracoxib among the entire study population (0.3 vs. 0.9%), 
as well as among those who were not taking aspirin (0.2 vs. 0.9%), but not in those taking 
aspirin. In a report summarizing the results of eterocoxib, based on three prospective 
randomized, double-blind trials (Laine et al., 2007), 34,701 arthritic patients were treated with 
60 or 90 mg of etoricoxib or 150 mg of diclofenac daily. This study included patients on low-
dose aspirin and/or PPI therapy. It was found that the overall incidence of uncomplicated GI 
events was significantly less with etoricoxib than with diclofenac (Hazard ratio 0.69, 95 % CI; 
0.57 – 0.83) (P < 0.001). There were no differences between the groups for complicated events 
(bleeding, perforation, and/or obstruction). 
A Cochrane systematic review of GI safety revealed that COX-2 inhibitors produced 
significantly fewer gastroduodenal ulcers (relative risk, 0.26; 95 % confidence interval, 0.23 – 
0.30) and ulcer complications (relative risk, 0.39; 95 % confidence interval, 0.31–0.50), as well 
as fewer withdrawals caused by GI symptoms when compared with nonselective NSAIDs 
(Rostom et al., 2007). 
6. Clinical spectrum of gastroduodenal mucosal injury by NSAIDs 
NSAIDs are valuable agents in the treatment of arthritis and many other musculoskeletal 
disorders, and as analgesics in a wide variety of clinical scenarios. However, as stated above, 
their use has been limited mainly by their association with mucosal injury to the upper 
gastrointestinal tract, including the development of peptic ulcer disease and its 
complications, most notably upper gastrointestinal hemorrhage and perforation (Cryer  & 
Feldman, 1992; Soll et al., 1991). 
6.1 Gastric damage 
Upper GI symptoms, such as dyspepsia, occur in 15% to 60% of NSAID users, twice as often 
as in individuals not taking NSAIDs. Dyspepsia occurs in three common patterns: ulcer-like 
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or acid dyspepsia (e.g., burning, epigastric hunger pain with food, antacid, and antisecretory 
agent relief); indigestion (also called functional dyspepsia or dysmotility-like dyspepsia, 
with postprandial belching, bloating, epigastric fullness, anorexia, early satiety, nausea, and 
occasional vomiting); and reflux-like dyspepsia. These patterns overlap considerably. 
Although poorly correlated with endoscopic lesions and clinical events, dyspepsia and other 
GI symptoms limit the use of NSAIDs, affect quality of life, and frequently require medical 
co-therapy with H2-receptor antagonists or PPIs. For example, it has been estimated that 5% 
to 15% of patients with rheumatoid arthritis can expect to discontinue NSAID therapy 
because of dyspepsia (Singh  & Triadafilopoulos, 1999). 
Endoscopically visible lesions associated with NSAID use include subepithelial 
hemorrhages, erosions, and ulcers. Subepithelial hemorrhages appear as bright red areas 
without any clear break in the mucosa. Microscopically, they appear as large numbers of red 
blood cells in the superficial portion of the mucosa, beneath the epithelium. Erosions are 
breaks in the mucosa that remain confined therein.  Subepithelial hemorrhages occur in 
virtually 100% of people within 15 to 30 minutes after ingestion of a single 650-mg dose of 
aspirin. Repeated dosing of aspirin (650 mg 4 times daily) leads to development of gastric 
erosions within 24 hours in virtually all patients (Laine, 1996). With longer-term therapy, 
adaptation may occur, although gastric erosions are still found in approximately 40% to 60% 
of patients taking regular doses of NSAIDs.  
An ulcer is defined histologically as a break that extends into the submucosa or deeper, and 
endoscopically as a break in the mucosa of >3 mm in diameter with unequivocal depth. For 
this reason, only ulcers can cause serious GI complications, such as bleeding, perforation, and 
obstruction. Subepithelial hemorrhages and erosions do not cause major GI bleeding because 
they are confined to the mucosal layer, where there are no blood vessels of significant size. 
Furthermore, they cannot cause the most dreaded of GI complications, perforation, since 
perforation requires an extension of the break in the mucosa through all 4 layers of the GI tract 
(mucosa, submucosa, musclaris propria, and serosa) (Laine, 2002). Ulcers may be formed in 
healthy subjects within 1 week of regular NSAID use. The prevalence of ulcers in patients 
taking NSAIDs regularly is approximately 15% to 30% (Laine, 1996; Larkai et al., 1987). The 
cumulative incidence of NSAID-associated ulcers in recent double-blind trials has been as high 
as 45% after 6 months. Most ulcers do not cause clinically important GI events. In fact, large 
outcome studies of arthritis patients indicate that the annual incidence of NSAID-related 
clinical upper GI events (complicated and symptomatic ulcers) is approximately 2.5% to 4.5%, 
while the annual incidence of serious complications (severe bleeding, perforation, and 
obstruction) is about 1% to 1.5%(Bombardier et al., 2000; Silverstein et al., 2000). Although 
these percentages are relatively small, the consumption of NSAIDs is so extensive that a large 
number of GI events are caused by NSAIDs, making GI complications the most important 
concern limiting use of NSAIDs. 
6.2 Duodenal damage 
In contrast to the stomach, damage to the duodenal mucosa by aspirin and NSAIDs seems to 
largely depend upon gastric acid. The "classic" symptoms of a duodenal ulcer occur when 
acid is secreted in the absence of a food buffer. Food is usually well emptied by two to three 
hours after meals, although food-stimulated acid secretion can persist for three to five hours; 
thus, classic duodenal ulcer symptoms occur two to five hours after meals or on an empty 
stomach. Symptoms also occur at night when the circadian stimulation of acid secretion is 
maximal. The ability of alkali, food, and antisecretory agents to produce relief suggests that 
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acid plays a role in this process. Thus, "acid dyspepsia" is a fitting term. Symptomatic 
periods lasting a few weeks, followed by symptom-free periods of weeks or months, is a 
pattern characteristic of classic duodenal ulcers. 
Numerous findings suggest that NSAIDs represent the most relevant factor in duodenal 
ulcers not associated with H. pylori infection. The history of NSAID use is more common in 
duodenal ulcer patients who have a normal, non-infected stomach than in those in whom 
the ulcer is associated with H. pylori gastritis.  Several studies have found either that NSAID 
intake is present in 25–75% of the H. pylori-negative duodenal ulcer patients or that NSAIDs 
are the most frequently identifiable cause in non-infected duodenal ulcers (Gisbert  & 
Calvet, 2009). 
6.3 Death rates associated with NSAIDs 
A very large study carried out by the Spanish National Health System reported a death rate 
of 15.3 persons per 100,000 NSAID users, including aspirin. Approximately 50% of the 
patients who died in the Spanish study had a prior history of one, or more, of the following 
risk factors: peptic ulceration, GI bleeding, dyspepsia, cardiac disease, or hypertension. The 
average age of patients dying from NSAID complications was 70±13.5 years and 89.7% of 
those who died were above age 60 (Lanas et al., 2005). In the United States the reported 
death rate associated with NSAIDs is three times higher than in Spain (Singh  & 
Triadafilopoulos, 1999), probably because this figure was extrapolated from a small sample 
of rheumatoid arthritis patients and it is well-known that rheumatoid arthritis alone has 
been associated with increased mortality, independent of NSAID use. 
7. Risk factors for NSAID-related GI complications 
Risk factors for GI complications associated with NSAIDs have been identified through a 
series of case–control and cohort studies that compared outcomes for patients taking these 
agents with those of control groups. A series of nested case–control studies based on 
incidence rates for hospitalization for GI bleeding in patients above age 65 showed an 
increased risk not only for this population group (odds ratio 4.7), but also for those on 
higher doses of NSAIDs (odds ratio 8.0), those who had a relatively short-term history of 
NSAID use (less than 1 month; odds ratio 7.2), and those concurrently taking corticosteroids 
(odds ratio 4.4) or anticoagulants (odds ratio 12.7) (Griffin et al., 1991; Griffin et al., 1988; 
Piper et al., 1991; Shorr et al., 1993) . In a large study series based on autopsy findings on 
patients with a history of NSAID use, gastric and duodenal ulcers were found to be more 
common among those who had consumed NSAIDs for less than 3 months (Allison et al., 
1992). Although the risk of ulcer complications decreases after the first few months of 
NSAID use, it does not disappear with long-term therapy. One approach to risk stratification 
has been proposed (Table 2) (Lanza et al., 2009). Gastrointestinal risk is arbitrarily stratified 
into low (i.e., no risk factors), moderate (presence of one or two risk factors), and high-risk 
groups (multiple risk factors, a history of ulcer complications, or concomitant use of 
corticosteroids or anticoagulants).  
8. Treatment and prevention of NSAID-related GI complications 
If a patient develops an ulcer while on NSAIDs, the relevant NSAID(s) should be stopped if 
at all possible and traditional ulcer therapy with a PPI or an H2 antagonist started. PPIs are 
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generally preferred as they are associated with more rapid healing. As in all patients with 
peptic ulcers, the individual's H. pylori status should also be assessed; if positive, 
appropriate therapy should be instituted. For patients who must remain on NSAID therapy 
or on low-dose aspirin, randomized trials have shown that ulcer healing occurs more 
rapidly with a PPI rather than with an H2 antagonist (Agrawal et al., 2000; Yeomans et al., 
1998), misoprostol (Hawkey et al., 1998), or sucralfate (Bianchi Porro et al., 1998). 
8.1 Prevention  
Most experts in the field agree that patients with a recent complicated peptic ulcer are at 
very high risk and it is best in such cases to avoid NSAID treatment entirely; however, if 
anti-inflammatory treatment must be undertaken, a COX-2 inhibitor plus misoprostol or a 
PPI therapy should be employed. Patients with a history of peptic ulcer disease, with or 




1. History of a previously complicated ulcer, especially if recent 
2. Multiple (>2) risk factors 
Moderate risk (1-2) 
1. Age > 65 
2. High-dose NSAID therapy 
3. A previous history of an uncomplicated ulcer 
4. Concurrent use of aspirin (including low dose), corticosteroids, or anticoagulants 
Low risk 
1. No risk factors 
H. pylori is an independent and additive risk factor and needs to be addressed separately  
Table 2. Patients at increased risk for NSAID GI toxicity (Guidelines for the Prevention of 
NSAID-related Ulcer Complications) (Lanza et al., 2009) 
dose), antiplatelet drugs (e.g., clopidrogel), anticoagulants (e.g., warfarin), or corticosteroids, 
or two or more risk factors also fall in the high-risk categories; here, treatment should 
consist of a COX-2 inhibitor and either misoprostol or PPI therapy (Lanza et al., 2009). As 
shown in Table 2, patients considered to be at moderate risk must be treated with a COX-2 
inhibitor alone or with an NSAID plus misoprostol or a PPI. Patients without risk factors are 
at low risk for NSAID-related peptic ulcer complications and no protective measures are 
required (Lanza et al., 2009) (Table 3). 
As mentioned above, multiple studies have evaluated the relationship between H. pylori and 
the risk of gastric ulcers in NSAID users. Based upon the available evidence, patients with a 
history of uncomplicated or complicated peptic ulcers (gastric, duodenal) should be tested 
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Gastrointestinal risk level 
Low Moderate High 
NSAID alone 
(the least ulcerogenic NSAID at 




Alternative therapy if 
possible or COX-2 
inhibitor+PPI/misoprostol 
Table 3. Treatment recommendations (Guidelines for the Prevention of NSAID-related Ulcer 
Complications) (Lanza et al., 2009) 
H. pylori should be treated with the appropriate therapy, even if it is believed that the prior 
ulcer was due to NSAIDs. In asymptomatic patients who have no history of ulcers and who 
are not currently taking a NSAID, physicians can consider H. pylori testing prior to 
beginning long-term therapy with a NSAID. One review of this topic found that eradication 
of H. pylori was beneficial in patients who were naïve to NSAIDs, while little benefit was 
observed in patients already taking and tolerating NSAIDs (Kiltz et al., 2008). This "test-and-
treat" approach may be more useful in populations with a relatively high prevalence of H. 
pylori infection. 
8.2 Misoprostol 
Misoprostol is a synthetic prostaglandin E1 analog that replaces the protective 
prostaglandins ingested during prostaglandin-inhibiting therapies. It was the first agent 
approved for the prevention of NSAID-related ulceration. Early studies in normal 
volunteers showed a marked reduction in the primary prevention of gastroduodenal lesion 
in patients receiving NSAIDs in combination with misoprostol, compared with those who 
received NSAIDs and a placebo (Lanza et al., 1989). A more recent meta-analysis revealed 
that co-therapy with misoprostol reduced the incidence of duodenal ulcers by 53% and 
gastric ulcers by 74%, when compared with placebo therapy (Rostom et al., 2002). Another 
study that compared a standard dose of misoprostol (200 mcg q.i.d.) with the PPI 
lansoprazole (in doses of 15 and 30 mg daily) in long-term NSAID users showed that 93% of 
patients taking misoprostol were protected from developing a gastric ulcer compared with 
80% and 82% in the two lansoprazole groups, respectively, over 12 weeks, and without any 
statistical significance among treated groups. Patients who were ulcer free after 12 weeks of 
therapy were kept on the same regimen for another 12 weeks, and at the end of that time 
43% of those on placebo, 83% on misoprostol, 83% on lansoprazole 30 mg, and 89% on 
lansoprazole 15 mg were still ulcer free (Graham et al., 2002) .  
Although misoprostol has proven to be effective in the prevention of GI complications 
induced by NSAIDs, it should be noted that its usefulness is limited in clinical settings by 
the occurrence of GI side effects, primarily cramping and diarrhea, and by compliance 
problems related to multiple dosage. 
8.3 Proton pump inhibitors (PPIs) 
PPIs have been utilized extensively as a co-therapy for the prevention of NSAID-induced 
peptic ulcers. Two large randomized controlled trials (Hawkey et al., 1998; Yeomans et al., 
1998) have been performed in osteoarthritis and rheumatoid arthritis patients comparing 
omeprazole with placebo therapy, misoprostol, and ranitidine in the secondary prevention 
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and healing of gastric and duodenal ulcers. In the first study, omeprazole (20 mg or 40 mg 
daily) co-therapy resulted in a significant reduction in the total number of NSAID-related 
ulcers when compared to ranitidine (150 mg orally twice a day). In the second study, 
omeprazol (20 mg daily) was more effective than misoprostol (800 mg daily) in preventing 
duodenal ulcers and in reducing gastric ulcers.  
The results of two similar multicenter randomized controlled trials have recently been 
published jointly (Scheiman et al., 2006). They compared esomeprazole 20 or 40 mg/daily 
with placebo therapy in preventing ulcers in patients taking NSAIDs or COX-2 inhibitors 
over a 6-month period. In the first study, which involved 844 patients, ulcer rates were 
20.4%, 5.3%, and 4.7% for placebo, esomeprazole 20 mg, and esomeprazole 40 mg, 
respectively. In the second study, which involved 585 patients, the respective ulcer rates 
were 12.3%, 5.2%, and 4.4 %. Patients in both studies were H. pylori-negative and were 
considered at-risk on the basis of age (above 60), or due to a history of documented gastric 
or duodenal ulcerations within 5 years of entry into the study. Both studies concluded that 
in at-risk patients, esomeprazole was effective at preventing ulcers in long-term users of 
NSAIDs, including COX-2 inhibitors. 
Thus, although full-dose misoprostol (200 mcg q.i.d.) is very effective in preventing NSAID-
related ulcers and their complications, as stated above, GI side effects limit its clinical use. 
Lower doses of misoprostol are not associated with cramps or diarrhea, but appear to be no 
more effective than standard PPI therapy. For all of these reasons, PPIs have assumed a 
dominant role in NSAID-related upper GI injury prophylaxis and therapy. A randomized 
trial of NSAID users who had H. pylori infection and prior ulcer bleeding (Chan et al., 2001) 
demonstrated that co-therapy with omeprazole was effective at preventing recurrent ulcer 
bleeding. Data from observational studies and secondary analyses of a large-scale 
randomized trial also indicate that PPIs reduce the risk of NSAID-associated ulcer bleeding. 
Maintenance therapy is indicated in patients who remain on or who resume NSAID 
treatment. 
There is no data suggesting that any of the available PPIs is more effective than another in 
treating NSAID-related GI damage.  
8.4 H2 receptor antagonists 
In most reports, standard doses of H2 receptor antagonists have shown no effectiveness in 
preventing NSAID-induced gastric ulcers. Systematic reviews have shown that double-dose 
(e.g., famotidine 40 mg two times daily) but not single-dose H2 receptor antagonists are 
effective at reducing the risk of NSAID-induced endoscopic gastric ulcers (Leontiadis et al., 
2007; Rostom et al., 2002). In patients taking low-dose aspirin, famotidine 20 mg twice daily 
can reduce the development of oesophagitis, gastric and duodenal ulcers by 80% in an 
average-risk population, when compared with placebo therapy (Taha et al., 2009). In 
contrast, a separate study from Hong Kong showed that high-dose famotidine (40 mg twice 
daily) was inferior to pantoprazole (20mg daily) in the prevention of gastroduodenal ulcers 
in patients at high risk of aspirin-related ulcers. Recurrent symptomatic or bleeding ulcers 
(20% versus 0%) and gastrointestinal bleeding (7.7% versus 0%) were more common in 
patients on famotidine than in those on pantoprazole (Ng et al., 2010). However, economic 
modeling suggests that co-therapy with H2 receptor antagonists may be a cost-effective 
strategy for the prevention of ulcer bleeding in NSAID users (Brown et al., 2006). Like PPIs, 
there have not been any randomized, clinical outcome trials that evaluate the efficacy of H2 
receptor antagonists in chronic NSAID users. 
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In high-risk patients, gastrointestinal complications associated with the use of NSAIDs are 
often caused by the concomitant use of aspirin or multiple NSAIDs, a failure to properly 
identify a patient's risk factors, and the underutilization of gastroprotective agents. The 
latter includes the use of PPIs in patients at high risk of gastrointestinal bleeding and the 
eradication of H. pylori in patients with a prior history of ulcers. PPIs have been shown to 
significantly reduce both gastric and duodenal ulcers and their attendant complications in 
patients taking not only NSAIDs, but also COX-2 inhibitors. Misoprostol, when given at full 
doses (800 mg/day) is very effective in preventing ulcers, and ulcer complications, in 
patients taking NSAIDs. However, its usefulness is limited in clinical practice due to its GI 
side effects. COX-2 inhibitors are associated with a significantly lower incidence of gastric 
and duodenal ulcers when compared to traditional NSAIDs. However, these beneficial 
effects are abrogated when the patient is concomitantly taking low-dose aspirin. 
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